Trial Profile

A pivotal phase 3 trial of VLX-1005 for treatment of Heparin-Induced Thrombocytopenia

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 29 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VLX-1005 (Primary)
Indications Heparin-induced thrombocytopenia and thrombosis syndrome
Focus Registrational; Therapeutic Use

Most Recent Events

29 Jan 2026 New trial record
12 Jan 2026 According to a Cadrenal Therapeutics media release, the company to engage with the U.S. Food and Drug Administration (FDA) to discuss the design of a potential pivotal Phase 3 registration study for VLX-1005 in HIT.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com